KR20230018387A - Il-17의 조절제로서의 이미다조피리미딘 - Google Patents

Il-17의 조절제로서의 이미다조피리미딘 Download PDF

Info

Publication number
KR20230018387A
KR20230018387A KR1020227041944A KR20227041944A KR20230018387A KR 20230018387 A KR20230018387 A KR 20230018387A KR 1020227041944 A KR1020227041944 A KR 1020227041944A KR 20227041944 A KR20227041944 A KR 20227041944A KR 20230018387 A KR20230018387 A KR 20230018387A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
methyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227041944A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 골드버그
코너 마틴
티모시 비. 로레
버지니아 엠. 타니스
시아오후아 슈에
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20230018387A publication Critical patent/KR20230018387A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
KR1020227041944A 2020-04-30 2021-04-28 Il-17의 조절제로서의 이미다조피리미딘 Withdrawn KR20230018387A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017679P 2020-04-30 2020-04-30
US63/017,679 2020-04-30
PCT/IB2021/053517 WO2021220183A1 (en) 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of il-17

Publications (1)

Publication Number Publication Date
KR20230018387A true KR20230018387A (ko) 2023-02-07

Family

ID=75769661

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041944A Withdrawn KR20230018387A (ko) 2020-04-30 2021-04-28 Il-17의 조절제로서의 이미다조피리미딘

Country Status (11)

Country Link
US (1) US12559496B2 (https=)
EP (1) EP4143193B1 (https=)
JP (1) JP7661361B2 (https=)
KR (1) KR20230018387A (https=)
CN (1) CN115867348B (https=)
AU (1) AU2021262588A1 (https=)
BR (1) BR112022021957A2 (https=)
CA (1) CA3181793A1 (https=)
IL (1) IL297734A (https=)
MX (1) MX2022013650A (https=)
WO (1) WO2021220183A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284283B2 (en) * 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3080131B1 (en) * 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
US10152431B2 (en) 2015-03-16 2018-12-11 Honeywell International Inc. System and method for remote set-up and adjustment of peripherals
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
IL279348B2 (en) * 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
JP7349491B2 (ja) * 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
MX2022013637A (es) 2020-04-30 2022-11-16 Janssen Pharmaceutica Nv Nuevos compuestos de triazinoindol.
MX2022013649A (es) 2020-04-30 2023-02-01 Janssen Pharmaceutica Nv Métodos para identificar moduladores de la ruta de il-17.

Also Published As

Publication number Publication date
EP4143193A1 (en) 2023-03-08
WO2021220183A1 (en) 2021-11-04
CN115867348B (zh) 2025-05-06
EP4143193B1 (en) 2026-04-22
IL297734A (en) 2022-12-01
CN115867348A (zh) 2023-03-28
MX2022013650A (es) 2023-02-01
JP2023523770A (ja) 2023-06-07
JP7661361B2 (ja) 2025-04-14
AU2021262588A1 (en) 2023-01-19
US20230242537A1 (en) 2023-08-03
BR112022021957A2 (pt) 2023-01-17
CA3181793A1 (en) 2021-11-04
US12559496B2 (en) 2026-02-24

Similar Documents

Publication Publication Date Title
KR20230018387A (ko) Il-17의 조절제로서의 이미다조피리미딘
JP7664947B2 (ja) Ｉｌ－１７の調節因子としてのイミダゾリダジン
RU2684324C1 (ru) Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4
KR20190040502A (ko) 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
US10047092B2 (en) Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
KR20200089706A (ko) 술폰 피리딘 알킬 아미드-치환된 헤테로아릴 화합물
SG172982A1 (en) Agonists and antagonists of the s1p5 receptor, and methods of uses thereof
EP4200275A2 (en) Fumarate derivatives and their medical use
US6710064B2 (en) Hydantoin compounds useful as anti-inflammatory agents
JP2019059728A (ja) Ｒｏｒγｔのモジュレーターとしてのトリフルオロメチルアルコール
KR20240082371A (ko) 이미다조피리다진 il-17 억제제 화합물
EA030204B1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
JP2021527660A (ja) ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
KR20240115978A (ko) Lpa 수용체 길항제 및 이의 용도
JP2023547470A (ja) インターロイキン－１７阻害剤
AU2017378316A1 (en) Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
EP2757103A1 (en) Pyrrolidine-3-ylacetic acid derivative
JP2023513121A (ja) Ａｄａｍｔｓ阻害剤、その製造および医薬用途
EP1367058B1 (en) Tetrahydropyran derivatives
US20250188079A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
JP7333321B2 (ja) 免疫プロテアソーム阻害剤
US8476301B2 (en) Pyrrolidin-3-ylacetic acid derivative
HK1193407B (en) Pyrrolidine-3-ylacetic acid derivative
HK1198034A (en) Pyrrolidine-3-ylacetic acid derivative

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202